Compounded Tirzepatide: Cost, Dosing, and Sourcing Guide (2026)

Compounded tirzepatide followed a nearly identical arc to compounded semaglutide: brand supply tightened, the price gap between Mounjaro and the compounded version became impossible to ignore, and demand for research-grade tirzepatide from peptide vendors climbed sharply. Brand Mounjaro and Zepbound list at $1,000 to $1,100 per month without insurance. Compounded tirzepatide from a 503B outsourcing facility typically runs $250 to $500. Research-grade tirzepatide from a reputable peptide vendor runs lower still.

This guide covers what compounded tirzepatide actually is, how it differs from the brand product, what dosing protocols look like, what quality markers matter when evaluating a source, and how the regulatory landscape stood as of mid-2026.

What Is Compounded Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide. Its sequence is a 39-amino-acid synthetic peptide that binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Eli Lilly holds the brand patents for Mounjaro (type 2 diabetes indication, approved May 2022) and Zepbound (obesity indication, approved November 2023). Both use the same active molecule at the same doses.

The dual receptor mechanism distinguishes tirzepatide from GLP-1-only agents like semaglutide. GIP receptor activation on fat cells and the central nervous system adds a layer of effect on top of GLP-1 satiety signaling, which is the mechanistic explanation for the larger average weight loss numbers seen in the SURMOUNT trials versus the STEP trials for semaglutide.

Compounded tirzepatide refers to tirzepatide prepared outside of Eli Lilly's manufacturing process. There are three main categories:

• 503B outsourcing facilities: FDA-registered facilities producing sterile compounded drugs at scale under cGMP standards. The highest quality tier of compounded pharmaceutical product, with required sterility and endotoxin testing per batch.
• 503A compounding pharmacies: Traditional compounding pharmacies filling individual prescriptions. Less rigorous FDA oversight than 503B. Quality varies considerably. Legally require a valid prescription.
• Research peptide vendors: Sell tirzepatide as a research chemical for laboratory use. Not for human administration. No prescription required. Quality ranges widely depending on the vendor; third-party COA is the minimum bar for a credible source.

Compounded Tirzepatide vs Brand: What Is and Is Not the Same

Standard Dosing Protocols

The FDA-approved titration schedules for Mounjaro and Zepbound are the most widely referenced protocols. Both indications use the same escalation schedule; the difference is the maximum approved dose for each label and the intended therapeutic goal.

Zepbound Titration (Weight Loss Indication)

Research protocols generally follow the same 4-week hold at each step. Some protocols extend holds to 6 to 8 weeks per step to reduce GI side effects or to assess response before escalating further. The 10 mg and 12.5 mg maintenance doses are clinically effective for many research subjects; the 15 mg dose added incremental benefit in the SURMOUNT trials but also higher GI side effect rates.

SURMOUNT-1 Trial Data by Dose

The SURMOUNT-1 trial was the pivotal weight loss study for tirzepatide, enrolling 2,539 adults with obesity over 72 weeks. Average weight loss by dose arm:

At the 15 mg dose, 91% of participants achieved at least 5% body weight loss and 57% achieved at least 20% -- figures that substantially exceed what the STEP semaglutide trials showed at comparable follow-up. For full dose-level analysis and comparison to the Mounjaro diabetes trials, see the tirzepatide dosage guide.

What Compounded Tirzepatide Is Typically Sold As

Research peptide vendors sell tirzepatide in two main forms:

• Lyophilized powder: Freeze-dried, typically 5 mg, 10 mg, 20 mg, or 30 mg per vial. Requires reconstitution with bacteriostatic water before use. More stable for shipping and long-term storage before reconstitution. See the peptide reconstitution guide for step-by-step instructions.
• Pre-mixed solution: Already dissolved in bacteriostatic water, typically at 5 mg/mL or 10 mg/mL concentration. Convenient but slightly more fragile in transit. Requires refrigeration throughout.

A 3 mL vial at 10 mg/mL contains 30 mg total tirzepatide. Working through the full Zepbound titration from 2.5 mg to 15 mg weekly requires approximately 140 mg total over the 20-week escalation period, not counting maintenance. Most researchers source multiple vials to cover a full protocol cycle.

How to Evaluate a Compounded Tirzepatide Source

Quality in the research peptide space is not uniform. The following markers separate credible vendors from unreliable ones:

Third-Party COA

A certificate of analysis from an independent testing laboratory is non-negotiable. The COA should show:

• Purity by HPLC: reputable vendors show 98% or higher
• Molecular weight confirmation (tirzepatide: 4813.47 g/mol)
• Peptide identity by mass spectrometry
• Batch number that matches the product shipped

COAs should be batch-specific, not a single document applied to all products. Tirzepatide is a longer peptide (39 amino acids) than most research peptides, which makes synthesis more technically demanding and makes independent purity verification more important, not less.

Salt Form Disclosure

Research vendors commonly sell tirzepatide as the acetate salt. The free base and trifluoroacetate (TFA) salt forms also exist. Dosing calculations are typically based on the acetate form; confirm the salt form before cross-referencing any dosing reference or protocol.

Storage and Reconstitution Specs

Lyophilized tirzepatide should be stored at -20C before reconstitution and used within 28 days of mixing when refrigerated at 2 to 8C, protected from light. Vendors that publish clear, specific storage specs signal product knowledge. Generic or absent instructions are a yellow flag.

Side Effects and What the Data Shows

The side effect profile for tirzepatide is well-documented from the SURMOUNT and SURPASS trial programs. GI effects are the most common and are dose-dependent:

• Nausea: Reported in 30 to 40% of participants at higher doses. Most common at initiation and dose escalation steps. Typically resolves within 4 to 8 weeks at any given dose level.
• Diarrhea: Reported in 17 to 23% across dose arms in SURMOUNT-1.
• Vomiting: Reported in 8 to 14%, higher at the 15 mg dose.
• Constipation: Reported in 10 to 12%.
• Reduced appetite / early satiety: The primary intended mechanism for weight loss; often experienced as the compound working rather than an adverse effect.

GI tolerability is the primary reason for the 4-week escalation cadence. The SURMOUNT-1 dropout rate for adverse events was approximately 4.3% in the tirzepatide groups versus 2.1% in placebo. Serious adverse events included pancreatitis and gallbladder disease at rates consistent with the GLP-1 drug class. The thyroid C-cell signal flagged in animal studies for GLP-1 agonists is included in the Zepbound label as a class-level precaution.

For a full breakdown of the side effect profile across doses and how it compares to semaglutide, see the tirzepatide side effects guide.

Compounded Tirzepatide and the FDA: The 2024 to 2026 Landscape

Eli Lilly's Mounjaro and Zepbound faced significant supply constraints through 2023 and into 2024, which prompted the FDA to add tirzepatide to the drug shortage list. Under shortage designation, the legal basis for 503A and 503B compounders to produce tirzepatide expanded substantially, and demand from compounding pharmacies and research peptide vendors rose in parallel.

As Eli Lilly worked to resolve supply constraints through 2024 and 2025, the FDA issued guidance narrowing the compounding permissions for tirzepatide, similar to what occurred with semaglutide:

• 503B outsourcing facilities may produce compounded tirzepatide only for patients with a documented clinical need that the commercially available product cannot meet.
• 503A pharmacies continue to compound for individual prescriptions under state pharmacy board oversight, with details varying by state.
• Research peptide vendors operate outside the pharmaceutical compounding framework and sell for non-human research use. This regulatory category was not directly affected by the shortage designation changes, though the FDA has signaled closer attention to the research peptide market for GLP-1 class compounds.

Researchers sourcing tirzepatide for laboratory purposes should monitor FDA compounding guidance pages for updates. The GLP-1 category has seen more enforcement attention than most peptide categories as the branded market has grown.

How Compounded Tirzepatide Compares to Other Weight Loss Peptides

Tirzepatide sits at the high end of the weight loss peptide landscape by efficacy. The broader options for 2026 research:

For a direct head-to-head on the two approved compounds, see the semaglutide vs tirzepatide guide. For cost comparisons across the brand landscape, the tirzepatide cost breakdown covers Mounjaro and Zepbound out-of-pocket pricing, manufacturer coupons, and how compounded options compare on a per-dose basis.

Sourcing Tirzepatide for Research: What Matters

Tirzepatide is a significantly more complex synthesis than most peptides in the research market. Its 39-amino-acid sequence, its fatty acid chain modification (which drives the half-life similar to semaglutide's acylation), and the dual receptor binding requirements all make purity verification more consequential, not less. A vendor who provides a batch-specific COA from an independent lab with HPLC purity and mass spec identity is a meaningfully different product from one who cannot.

Pantheon and Apollo are two vendors that carry tirzepatide with third-party purity documentation. Both are referenced consistently in research peptide communities for meeting the minimum documentation bar. Verify the current batch COA on their product pages before ordering.